CynthiaASirardMD

PubMed

• 12 citations
  Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors.
  Davar, D., Zappasodi, R., Wang, H., Naik, G., Sato, T., Bauer, T., Bajor, D., Rixe, O., Newman, W., Qi, J., Holland, A., Wong, P., Sifferlen, L., Piper, D., Sirard, C....> ;Clinical Cancer Research. 2022 Sep 15
• Response to anti-DKK1 therapy in uterine carcinosarcoma: A case report.
  A ElNaggar, N Zhang, C B Scalise, C Sirard, M H Kagey, D Vaena, R Arend> ;Gynecologic Oncology Reports. 2022 Feb 1
• 20 citations
  Safety, Efficacy, and Biomarker Results from a Phase Ib Study of the Anti-DKK1 Antibody DKN-01 in Combination with Pembrolizumab in Advanced Esophagogastric Cancers.
  Samuel J. Klempner, Johanna C. Bendell, Victoria M. Villaflor, Laura LaNiel Tenner, Stacey Stein, James B. Rottman, Girish S. Naik, Cynthia A. Sirard, Michael H. Kagey...> ;Molecular Cancer Therapeutics. 2021 Sep 4
• 34 citations
  Phase I and biomarker study of the wnt pathway modulator dkn-01 in combination with gemcitabine/ cisplatin in advanced biliary tract cancer
  Lipika Goyal, Cynthia A. Sirard, Michael Schrag, Michael H. Kagey, Jennifer R. Eads, Stacey Stein, Anthony B. El-Khoueiry, Gulam Abbas Manji, Thomas A. Abrams, Alok A....> ;Clinical Cancer Research. 2020 Dec 1
• 25 citations
  Dickkopf-1 Can Lead to Immune Evasion in Metastatic Castration-Resistant Prostate Cancer
  David R. Wise, Jeffrey A. Schneider, Joshua Armenia, Victor Ricardo Adorno Febles, Bridget McLaughlin, Ryan Brennan, Katie L. Thoren, Wassim Abida, Karen S. Sfanos, An...> ;JCO Precision Oncology. 2020 Sep 29
• 69 citations
  Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial
  Thomas Elter, Liana Gercheva-Kyuchukova, Halyna Pylylpenko, Tadesuz Robak, Branimir Jakšić, Grigoriy B Rekhtman, Slawomira Kyrcz-Krzemien, Mykola Vatutin, Jingyang Wu,...> ;The Lancet. Oncology. 2011 Dec 1
• 1 citations
  Hillmen Trial of Alemtuzumab in First-Line Chronic Lymphocytic Leukemia Still Provides Valuable Information
  Cynthia A. Sirard, Elizabeth G. Trehu> ;Journal of Clinical Oncology. 2008 May 10
• 418 citations
  Alemtuzumab Compared With Chlorambucil As First-Line Therapy for Chronic Lymphocytic Leukemia
  Peter Hillmen, Aleksander B. Skotnicki, Tadeusz Robak, Branimir Jakšić, Anna Dmoszynska, Jingyang Wu, Cynthia A. Sirard, Jiri Mayer> ;Journal of Clinical Oncology. 2007 Dec 10
• Preliminary phase III efficacy and safety of alemtuzumab vs chlorambucil as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL).
  Hillmen P, Skotnicki A, Robak T, Jaksic B, Dmoszynska A, Sirard C, Mayer J> ;J. Clin. Oncol.. 2006-06-20
• Cytogenetic correlation with efficacy on alemtuzumab (CAM) vs chlorambucil (CHLO) as front-line therapy for patients with progressive B-cell chronic lymphocytic leukem...
  Dmoszynska A, Fetni R, Wang Y, Belkaci M, Sirard C, Goldberg M, Mayer J, Robak T, Skotnicki A, Hillmen P> ;J. Clin. Oncol.. 2006-06-20
• Join now to see all

Lectures

• Correlation of radiomics of metastatic lesions in gastroesophageal adenocarcinoma (GEA) with tumoral DKK1 mRNA expression and other immune biomarkers in patients (pts)... 
  ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/23/2020